A signboard of Chugai Pharmaceutical Co is seen on the firm manufacturing unit in Tokyo August 18, 2014. Chugai Pharmaceutical Co Ltd shares rose 21 p.c to a report excessive following a media report that Roche Holding AG is in talks to purchase the virtually 40 p.c stake within the Japanese agency that it would not already personal for about $10 billion. REUTERS/Toru Hanai (JAPAN – Tags: BUSINESS)
TOKYO, Oct 11 (Reuters) – Japan’s Chugai Pharmaceutical Co (4519.T) stated on Monday it has utilized to regulators to broaden the usage of an antibody therapy for COVID-19 to additionally enable for preventative care.
Japanese regulators authorised an antibody cocktail referred to as Ronapreve as a therapy for COVID-19 in July. The newest submitting seeks to make use of the drug as each a prophylaxis for COVID-19 and as therapy of asymptomatic circumstances, Chugai stated in a launch.
Reporting by Rocky Swift, Modifying by Timothy Heritage
Our Requirements: The Thomson Reuters Trust Principles.
0 Comments